Home/ Stocks/ MNKD

Mannkind Corporation

MNKD XNAS

$4.11 +0.19 (+4.88%) ▲ 15-min delayed

Open

$3.91

High

$4.15

Low

$3.85

Volume

5.05M

Market Cap

$1.25B

About Mannkind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 592 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$109.37M	$-19,032,000	$-0.06
Q1 2026	$90.17M	$-16,619,000	$-0.05
FY 2025	$348.97M	$5.86M	$0.02
Q3 2025	$82.13M	$7.99M	$0.03

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for MNKD yet. Check out our latest market news or earnings calendar.

Get MNKD Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Mannkind Corporation.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.